Mechanisms of vaccine-induced protective immunity against Coxiella burnetii infection in BALB/c mice
- PMID: 18056383
- DOI: 10.4049/jimmunol.179.12.8372
Mechanisms of vaccine-induced protective immunity against Coxiella burnetii infection in BALB/c mice
Abstract
To elucidate the mechanisms of vaccine-induced protective immunity against Coxiella burnetii infection, we compared the protective efficacy and immunogenicity between formalin-inactivated phase I vaccine (PI-V) and phase II vaccine (PII-V) in BALB/c mice. PI-V generated significant protection while PII-V did not confer measurable protection. Analysis of cytokine and subclass Ab responses indicated that both PI-V and PII-V were able to induce a Th1-dominant immune response but did not identify the component of host response that distinguished their ability to induce protective immunity. Interestingly, immunoblot analysis identified a difference between PI-V and PII-V vaccinates in antigenic recognition by specific Ab isotypes. The observation that PI-LPS elicited significant protection but PII-LPS did not confer measurable protection suggests PI-LPS may play a key role in PI-V-induced protection. Adoptive transfer of either immune sera or splenocytes mediated significant protection in naive BALB/c mice, supporting the notion that both humoral and cellular immunity are important for development of protective immunity. However, the evidence that immune sera and B cells were unable to control infection while T cells conferred significant protection in SCID mice supports the hypothesis that T cell-mediated immunity is critical for host defense against C. burnetii infection. This report presents novel evidence to highlight the importance of PI-LPS and Abs in protective immunity and has important implications for the design of new generation vaccines against Q fever.
Similar articles
-
Chemokine Receptor 7 Is Essential for Coxiella burnetii Whole-Cell Vaccine-Induced Cellular Immunity but Dispensable for Vaccine-Mediated Protective Immunity.J Infect Dis. 2019 Jul 19;220(4):624-634. doi: 10.1093/infdis/jiz146. J Infect Dis. 2019. PMID: 30938819 Free PMC article.
-
Formalin-inactivated Coxiella burnetii phase I vaccine-induced protection depends on B cells to produce protective IgM and IgG.Infect Immun. 2013 Jun;81(6):2112-22. doi: 10.1128/IAI.00297-13. Epub 2013 Apr 1. Infect Immun. 2013. PMID: 23545296 Free PMC article.
-
Development of a lipopolysaccharide-targeted peptide mimic vaccine against Q fever.J Immunol. 2012 Nov 15;189(10):4909-20. doi: 10.4049/jimmunol.1201622. Epub 2012 Oct 10. J Immunol. 2012. PMID: 23053512 Free PMC article.
-
Components of protective immunity.Adv Exp Med Biol. 2012;984:91-104. doi: 10.1007/978-94-007-4315-1_5. Adv Exp Med Biol. 2012. PMID: 22711628 Review.
-
Adaptive immunity to the obligate intracellular pathogen Coxiella burnetii.Immunol Res. 2009;43(1-3):138-48. doi: 10.1007/s12026-008-8059-4. Immunol Res. 2009. PMID: 18813881 Free PMC article. Review.
Cited by
-
Vaccination against Q fever for biodefense and public health indications.Front Microbiol. 2014 Dec 16;5:726. doi: 10.3389/fmicb.2014.00726. eCollection 2014. Front Microbiol. 2014. PMID: 25566235 Free PMC article.
-
Immunoreactive Coxiella burnetii Nine Mile proteins separated by 2D electrophoresis and identified by tandem mass spectrometry.Microbiology (Reading). 2011 Feb;157(Pt 2):526-542. doi: 10.1099/mic.0.043513-0. Epub 2010 Oct 28. Microbiology (Reading). 2011. PMID: 21030434 Free PMC article.
-
Multivalent vaccines demonstrate immunogenicity and protect against Coxiella burnetii aerosol challenge.Front Immunol. 2023 Jul 18;14:1192821. doi: 10.3389/fimmu.2023.1192821. eCollection 2023. Front Immunol. 2023. PMID: 37533862 Free PMC article.
-
Q Fever Vaccines: Unveiling the Historical Journey and Contemporary Innovations in Vaccine Development.Vaccines (Basel). 2025 Jan 31;13(2):151. doi: 10.3390/vaccines13020151. Vaccines (Basel). 2025. PMID: 40006698 Free PMC article. Review.
-
Contributions of lipopolysaccharide and the type IVB secretion system to Coxiella burnetii vaccine efficacy and reactogenicity.NPJ Vaccines. 2021 Mar 19;6(1):38. doi: 10.1038/s41541-021-00296-6. NPJ Vaccines. 2021. PMID: 33741986 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous